Diverse ecdysterones show different effects on amyloid-β42 aggregation but all uniformly inhibit amyloid-β 42-induced cytotoxicity

Journal of Alzheimer's Disease

Volumn 22, Issue 1, 2010, Pages 107-117

  Yang, Shi Gao ^a   Zhang, Xi ^a   Sun, Xiao Sia ^a   Ling, Tie Jun ^b   Feng, Ying ^a   Du, Xue Ying ^a   Zhao, Min ^a   Yang, Yang ^a   Xue, Di ^a   Wang, Li ^a   Liu, Rui Tian ^a  

^a Tsinghua University   (China)

^b ANHUI AGRICULTURAL UNIVERSITY   (China)

Author keywords

Aggregation; Alzheimer's disease; amyloid ; ecdysterone; Klaseopsis chinensis; neurotoxicity

Indexed keywords

2 O ACETYL 20 HYDROXYECDYSONE; 25,26 DIDEHYDROPONASTERONE A; 3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; 3 O ACETYL 20 HYDROXYECDYSONE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-42]; CARTHAMOSTERONE; ECDYSTERONE; OLIGOMER; REACTIVE OXYGEN METABOLITE; STACHYSTERONE C; THIOFLAVINE; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; ARTICLE; CELL PROTECTION; HUMAN; HUMAN CELL; NEUROPROTECTION; NEUROTOXICITY; PRIORITY JOURNAL; PROTEIN AGGREGATION; STRUCTURE ACTIVITY RELATION;

EID: 78650658901     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-100621     Document Type: Article

References (46)

1. Parihar MS, Hemnani T (2004) Alzheimer's disease pathogen-esis and therapeutic interventions. J Clin Neurosci 11, 456467.
2. Blennow K, de Leon MJ, Zetterberg H (2006) Alzheimer's disease. Lancet 368, 387-403.
3. Jacob-Roetne R, Jacobsen H (2009) Alzheimer's disease: from pathology to therapeutic approaches. Angew Chem Int Ed 48, 3030-3059.
4. Resende R, Ferreiro E, Pereira C, Resende de Oliveira C (2008) Neurotoxic effect ofoligomeric and fibrillar species of amyloid-beta peptide 1-42: involvement ofendoplasmic retic-ulum calcium release in oligomer-induced cell death. Neuro-science 155, 725-737.
5. Diaz JC, Simakova O, Jacobson KA, Arispe N, Pollard HB (2009) Small molecule blockers ofthe Alzheimer Abeta calcium channel potently protect neurons from Abeta cytotoxicity. Proc Natl Acad Sci USA 106, 3348-3353.
6. Nunomura A, Tamaoki T, Tanaka K, Motohashi N, Nakamura M (2010) Intraneuronal amyloid beta accumulation and oxidative damage to nucleic acids in Alzheimer disease. Neurobiol Dis 37, 731-737.
7. Nunomura A, Hofer T, Moreira PI, Castellani RJ, Smith MA (2009) RNA oxidation in Alzheimer disease and related neu-rodegenerative disorders. Acta Neuropathol 118, 151-166.
8. Stuve O, Youssef S, Steinman L, Zamvil SS (2003) Statins as potential therapeutic agents in neuroinflammatory disorders. Curr Opin Neurol 16, 393-401.
9. Aisen PS (2002) The potential of anti-inflammatory drugs for the treatment of Alzheimer's disease. Lancet Neurol 1, 279284.
10. Liu R, Barkhordarian H, Emadi S, Park CB, Sierks MR (2005) Trehalose differentially inhibits aggregation and neurotoxicity of beta-amyloid 40 and 42. Neurobiol Dis 20, 74-81.
11. Yang F, Lim GP, Begum AN, Ubeda OJ, Simmons MR, Am-begaokar SS, Chen P, Kayed Rakez, Glabe CG, Frautschy SA and Cole GM (2005) Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo.J Biol Chem 280, 5892-5901.
12. Feng Y, Wang XP, Yang SG, Wang YJ, Zhang X, Du XT, Sun XX, Zhao M, Huang L, Liu RT (2009) Resveratrol inhibits beta-amyloid oligomeric cytotoxicity but does not prevent oligomer formation. Neurotoxicology 30, 986-995.
13. Dinan L (2001) Phytoecdysteroids: biological aspects. Phyto-chemistry 57, 325-339.
14. Xu NJ, Guo YY, Li X (1997) Advances in Pharmacological Research on Ecdysterone. J Shenyang Pharm Univ 14, 300302.
15. Ming-hua Q (2004) Ecdysterones, what roles do they play in life world? Chin J Nature 27, 25-28.
16. Gorelick-Feldman J, Maclean D, Ilic N, Poulev A, Lila MA, Cheng D, Raskin I (2008) Phytoecdysteroids increase protein synthesis in skeletal muscle cells. J Agric Food Chem 56, 3532-3537.
17. Chen Q, Xia Y, Qiu Z (2006) Effect of ecdysterone on glucose metabolism in vitro. Life Sci 78, 1108-1113.
18. Uchiyama M, Yoshida T (1974) Effect of ecdysterone on carbohydrate and lipid metabolism. Invertebrate Endocrinology andHormonal Heterophylly, Burdette WJ, eds. Springer Ver-lag, pp. 401-416.
19. Kosar K, Opletal L, Vokac K, Harmatha J, Sovova M, Cerovsky J, Kratky F, Dvorak J (1997) Embryotoxici-ty of 20-hydroxyecdysone and polypodine B from Leuzea carthamoides DC. Pharmazie 52, 406-407.
20. Slariia K, Lafont, R (1995) Insect hormones-ecdysteroids: their presence and actions in vertebrates. Eur J Entomol 92, 355-377.
21. Sahach VF, Korkach Iu P, Kotsiuruba AV, Prysiazhna OD (2008) The inhibition of oxidative and nitrosative stresses by ecdysterone as the mechanisms of its cardio-and vasopro-tective action in experimental diabetes type I. Fiziol Zh 54, 46-54.
22. Danylovych Iu V (2004) Effect of steroid hormones and oxy-tocin on NO and H2 O2 production in the endometrium. Ukr Biokhim Zh 76, 88-96.
23. Kuz'menko AI, Morozova RP, Nikolenko IA, Donchenko GV (1999) Characteristics of antioxidant properties of 20-hydroxyecdysone in low density lipoproteins by kinetic parameters of chemiluminescence. Ukr Biokhim Zh 71, 37-42.
24. Xu Nanjie, Li Xian (1999) The Improving Effect of Ecdysterone on Learning and Memory in Mice. J Shenyang Pharm Univ 16, 16-19.
25. Su-fen Y (2004) The effects of ecdysterone on the expressions of c-fos gene from the brain of the rats. Acta Acad Med Zunyi 27, 5-7.
26. Wu J (2001) Experimental Study on the anti-aging effect of β-ecdysterone. Natural Product Res Devel 13, 28-29.
27. Wang XP, Zhang JH, Wang YJ, Feng Y, Zhang X, Sun XX, Li JL, Du XT, Mary P. Lambert, Yang SG, Zhao M, William L. Klein, Liu RT (2009) Conformation-dependent single-chain variable fragment antibodies specifically recognize beta-amyloid oligomers. FEBSLett 583, 579-584.
28. Lafont R. HJ, Marion-Poll F, Dinan L, Wilson I (2008) The Ecdysone Handbook, 3rdedition. (http://ecdybase.org).
29. Gunther EC, Strittmatter SM (2010) Beta-amyloid oligomers and cellular prion protein in Alzheimer's disease. J Mol Med 88,331-338.
30. Nakagami Y, Nishimura S, Murasugi T, Kaneko I, Meguro M, Marumoto S, Kogen H, Koyama K, Oda T (2002) A novel beta-sheet breaker, RS-0406, reverses amyloid beta-induced cytotoxicity and impairment oflong-term potentiation in vitro. Br J Pharmacol 137, 676-682.
31. Austen BM, Paleologou KE, Ali SA, Qureshi MM, Allsop D, El-Agnaf MA (2008) Designing peptide inhibitors for oligomerization and toxicity ofAlzheimer's beta-amyloid pep-tide. Biochemistry 47, 1984-1992.
32. Soto P, Griffin MA, Shea JE (2007) New insights into the mechanism of Alzheimer amyloid-beta fibrillogenesis inhibition by N-methylated peptides. Biophys J 93, 3015-3025.
33. Robert R (2009) Engineered antibody intervention strategies for Alzheimer's disease and related dementias by targeting amyloid and toxic oligomers. Protein Engineering Design Selection 22, 199-208.
34. Zameer A, Schulz P, Wang MS, Sierks MR (2006) Single chain Fv antibodies against the 25-35 Abeta fragment inhibit aggregation and toxicity of AbetaBiochemistry 45, 1153211539.
35. Legleiter J, Czilli DL, Gitter B, DeMattos RB, Holtzman DM, Kowalewski T (2004) Effect of different anti-Abeta antibodies on Abeta fibrillogenesis as assessed by atomic force microscopy. J Mol Biol 335, 997-1006.
36. Wang YJ, Pollard A, Zhong JH, Dong XY, Wu XB, Zhou HD, Zhou XF (2009) Intramuscular delivery of a single chain antibody gene reduces brain Abeta burden in a mouse model of Alzheimer's disease. Neurobiol Aging 30, 364-376.
37. Chromy BA, Nowak RJ, Lambert MP, Viola KL, Chang L, Velasco PT, Jones BW, Fernandez SJ, Lacor PN, Horowitz P, Finch CE, Krafft GA, Klein WL (2003) Self-assembly of Abeta(1-42) into globular neurotoxins. Biochemistry 42, 12749-12760.
38. Li J, Zhu M, Manning-Bog AB, Di Monte DA, Fink AL (2004) Dopamine and L-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J 18, 962-964.
39. Bergamaschini L, Rossi E, Storini C, Pizzimenti S, Distaso M, Perego C, De Luigi A, Vergani C, De Simoni MG (2004) Peripheral treatment with enoxaparin, a low molecular weight heparin, reduces plaques and beta-amyloid accumulation in a mouse model of Alzheimer's disease. J Neurosci 24, 41814186.
40. Bartolini M, Bertucci C, Bolognesi ML, Cavalli A, Melchiorre C, Andrisano V (2007) Insight into the kinetic of amyloid beta (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action. Chembiochem 8, 2152-2161.
41. Honson NS, Johnson RL, Huang W, Inglese J, Austin CP, Kuret J (2007) Differentiating Alzheimer disease-associated aggregates with small molecules. Neurobiol Dis 28, 251-260.
42. Feng Y, Yang SG, Du XT, Zhang X, Sun XX, Zhao M, Sun GY, Liu RT (2009) Ellagic acid promotes Abeta42 fibrillization and inhibits Abeta42-induced neurotoxicity. Biochem Biophys Res Commun 390, 1250-1254.
43. Haass C, Selkoe DJ (2007) Soluble protein oligomers in neu-rodegeneration: lessons from the Alzheimer's amyloid beta-peptide. Nat Rev Mol Cell Biol 8, 101-112.
44. Necula M, Breydo L, Milton S, Kayed R, van der Veer WE, Tone P, Glabe CG (2007) Methylene blue inhibits amyloid Abeta oligomerization by promoting fibrillization. Biochemistry 46, 8850-8860.
45. Durairajan SS, Yuan Q, Xie L, Chan WS, Kum WF, Koo I, Liu C, Song Y, Huang JD, Klein WL, Li M (2008) Salvianolic acid B inhibits Abeta fibril formation and disaggregates preformed fibrils and protects against Abeta-induced cytotoxicty. Neurochem Int 52, 741-750.
46. Mamikonyan G, Necula M, Mkrtichyan M, Ghochikyan A, Petrushina I, Movsesyan N, Mina E, Kiyatkin A, Glabe CG, Cribbs DH, Agadjanyan MG(2007) Anti-Abeta 1-11 antibody binds to different beta-amyloid species, inhibits fibril formation, and disaggregates preformed fibrils but not the most toxic oligomers. J Biol Chem 282, 22376-22386.